sNN 0031 / Newron - LARVOL DELTA

A Follow-up Study on Safety and Tolerability of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease (clinicaltrials.gov) - P=N/A; N=11; Completed; Sponsor: NeuroNova AB; Active, not recruiting -> Completed ; Trial primary completion date: Nov 2013 ->Aug 2014

Trial completion • Trial primary completion date • Biosimilar • Immunology • Parkinson's Disease